Overview
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Eligibility
Inclusion Criteria:
- Diagnosis of Familial Partial Lipodystrophy (FPLD)
- Subjects with poor metabolic control defined as:
HbA1c ≥7% (at Visit 1 and Visit 3) and/or Fasting TGs ≥500 mg/dL (5.65 mmol/L, at Visit 1 and Visit 3)
- Patients should be receiving optimized stable therapy
Exclusion Criteria:
- Previous treatment with metreleptin
- Leptin levels >20.0 ng/mL
- Acquired or radiation induced partial lipodystrophy (APL)
Other protocol defined inclusion/exclusion criteria apply